Bicycle Therapeutics plc Increase (Decrease) in Accounts Receivable
Bicycle Therapeutics plc (BCYC) reported Increase (Decrease) in Accounts Receivable of $133.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-04-30
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $133.00K.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was $49.88M.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was -$49.84M, a 582.14% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for fiscal 2023 was -$2.48M, a 251.25% decline from fiscal 2022.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for fiscal 2022 was $1.64M.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for fiscal 2021 was -$4.54M, a 311.40% decline from fiscal 2020.
- Bicycle Therapeutics plc increase (decrease) in accounts receivable for fiscal 2020 was $2.15M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2025-03-31 | $133.00K 10-Q · filed 2026-04-30 | |||
| 2024-06-30 | $232.00K 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $49.88M derived: sum of 2 quarters · filed 2026-03-17 | $37.00K derived: sum of 3 quarters · filed 2026-03-17 | -$2.48M 10-K · filed 2026-03-17 |
| 2023-09-30 | $49.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $37.00K derived: sum of 2 quarters · filed 2024-10-31 | -$2.48M 10-Q · filed 2024-10-31 | -$493.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$49.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$52.36M 10-Q · filed 2024-08-06 | -$50.37M derived: sum of 3 quarters · filed 2025-02-25 | -$60.06M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$2.52M 10-Q · filed 2024-05-02 | -$530.00K derived: sum of 2 quarters · filed 2025-02-25 | -$10.22M derived: sum of 3 quarters · filed 2025-02-25 | $113.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$7.71M derived: sum of 2 quarters · filed 2025-02-25 | $2.63M derived: sum of 3 quarters · filed 2025-02-25 | $1.64M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$9.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $643.00K derived: sum of 2 quarters · filed 2023-11-02 | -$348.00K 10-Q · filed 2023-11-02 | $653.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $10.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $9.35M 10-Q · filed 2023-08-03 | $10.35M derived: sum of 3 quarters · filed 2024-02-20 | $10.35M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$991.00K 10-Q · filed 2023-05-04 | $10.00K derived: sum of 2 quarters · filed 2024-02-20 | $10.00K derived: sum of 3 quarters · filed 2024-02-20 | -$2.01M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.00M derived: sum of 2 quarters · filed 2024-02-20 | -$1.02M derived: sum of 3 quarters · filed 2024-02-20 | -$4.54M 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.02M derived: sum of 2 quarters · filed 2022-11-03 | -$5.54M 10-Q · filed 2022-11-03 | -$6.08M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$5.54M 10-Q · filed 2022-08-04 | -$6.08M derived: sum of 3 quarters · filed 2023-02-28 | -$3.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$3.52M 10-Q · filed 2022-05-05 | -$4.06M derived: sum of 2 quarters · filed 2023-02-28 | -$1.70M derived: sum of 3 quarters · filed 2023-02-28 | -$2.22M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.82M derived: sum of 2 quarters · filed 2023-02-28 | $1.30M derived: sum of 3 quarters · filed 2023-02-28 | $2.15M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.84M derived: sum of 2 quarters · filed 2021-11-04 | $2.69M 10-Q · filed 2021-11-04 | $2.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $332.00K 10-Q · filed 2021-08-05 | $487.00K derived: sum of 3 quarters · filed 2022-03-01 | $378.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $846.00K 10-Q · filed 2021-05-06 | $1.00M derived: sum of 2 quarters · filed 2022-03-01 | $892.00K derived: sum of 3 quarters · filed 2022-03-01 | $797.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $46.00K derived: sum of 2 quarters · filed 2022-03-01 | -$49.00K derived: sum of 3 quarters · filed 2022-03-01 | -$4.91M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$204.00K derived: sum of 2 quarters · filed 2020-11-05 | -$5.06M 10-Q · filed 2020-11-05 | -$4.95M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | -$95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$4.96M 10-Q · filed 2020-08-05 | -$4.84M derived: sum of 3 quarters · filed 2021-03-11 | -$6.09M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$4.86M 10-Q · filed 2020-05-07 | -$4.75M derived: sum of 2 quarters · filed 2021-03-11 | -$6.00M derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$1.14M derived: sum of 2 quarters · filed 2021-03-11 | $400.00K 10-K · filed 2021-03-11 | |
| 2018-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $289.00K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $1.54M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |